阿贝西利联合内分泌治疗用于高风险早期乳腺癌的辅助治疗:monarchE研究的安全性与患者报告结局
monarchE研究在中位随访27个月时,对接受至少一剂研究治疗的患者(n=5591)进行安全性分析。阿贝西利联合内分泌治疗相比单用内分泌治疗,3级及以上不良事件发生率更高(49.7% vs 16.3%),严重不良事件更多(15.2% vs 8.8%);患者报告结局两组相似,仅腹泻存在差异。结论认为该方案安全性可接受,不良事件多可逆且可通过药物和/或剂量调整管理。
要点
- 阿贝西利联合内分泌治疗组3级及以上不良事件发生率为49.7%,单用内分泌治疗组为16.3%。
- 阿贝西利组严重不良事件发生率为15.2%,单用内分泌治疗组为8.8%。
- 两组患者报告结局相似,仅腹泻存在差异。
核心结论
- 在高风险早期乳腺癌患者中,阿贝西利联合内分泌治疗作为辅助治疗具有可接受的安全性,患者报告结局支持其耐受性。
- 大多数不良事件可逆,可通过合并用药和/或剂量调整管理,与已知的阿贝西利毒性特征一致。
研究设计与样本
- monarchE研究的安全性分析,纳入所有接受至少一剂研究治疗的患者(n=5591)。
- 安全性分析包括常见及临床相关不良事件的发生率、管理和结局。
- 评估患者报告的健康相关生活质量、内分泌治疗症状、疲劳及副作用负担。
主要发现
- 阿贝西利联合内分泌治疗组3级及以上不良事件发生率为49.7%,单用内分泌治疗组为16.3%。
- 阿贝西利联合内分泌治疗组严重不良事件发生率为15.2%,单用内分泌治疗组为8.8%。
- 因不良事件停用阿贝西利和/或内分泌治疗的患者占18.5%,其中66.8%主要因1/2级不良事件停药。
- 腹泻多为低级别(1/2级:76%),2/3级事件在第一个月最高(20.5%),多数持续时间短(≤7天)且未复发。
- 静脉血栓栓塞事件在阿贝西利联合内分泌治疗组为2.5%,单用内分泌治疗组为0.6%;阿贝西利组中他莫昔芬相比芳香化酶抑制剂的血栓风险增加(4.3% vs 1.8%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In monarchE, abemaciclib plus endocrine therapy (ET) as adjuvant treatment of hormone receptor-positive, human epidermal growth factor 2-negative, high-risk, early breast cancer (EBC) demonstrated a clinically meaningful improvement in invasive disease-free survival versus ET alone. Detailed safety analyses conducted at a median follow-up of 27 months and key patient-reported outcomes (PROs) are presented. PATIENTS AND METHODS: The safety population included all patients who received at least one dose of study treatment (n = 5591). Safety analyses included incidence, management, and outcomes of common and clinically relevant adverse events (AEs). Patient-reported health-related quality of life, ET symptoms, fatigue, and side-effect burden were assessed. RESULTS: The addition of abemaciclib to ET resulted in higher incidence of grade ≥3 AEs (49.7% versus 16.3% with ET alone), predominantly laboratory cytopenias [e.g. neutropenia (19.6%)] without clinical complications. Abemaciclib-treated patients experienced more serious AEs (15.2% versus 8.8%). Discontinuation of abemaciclib and/or ET due to AEs occurred in 18.5% of patients, mainly due to grade 1/2 AEs (66.8%). AEs were managed with comedications (e.g. antidiarrheals), abemaciclib dose holds (61.7%), and/or dose reductions (43.4%). Diarrhea was generally low grade (grade 1/2: 76%); grade 2/3 events were highest in the first month (20.5%), most were short-lived (≤7 days) and did not recur. Venous thromboembolic events (VTEs) were higher with abemaciclib + ET (2.5%) versus ET (0.6%); in the abemaciclib arm, increased VTE risk was observed with tamoxifen versus aromatase inhibitors (4.3% versus 1.8%). PROs were similar between arms, including being 'bothered by side-effects of treatment', except for diarrhea. At ≥3 months, most patients reporting diarrhea reported 'a little bit' or 'somewhat'. CONCLUSIONS: In patients with high-risk EBC, adjuvant abemaciclib + ET has an acceptable safety profile and tolerability is supported by PRO findings. Most AEs were reversible and manageable with comedications and/or dose modifications, consistent with the known abemaciclib toxicity profile.
引用
- Rugo HS, O'Shaughnessy J, Boyle F, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study. Ann Oncol. 2022. PMID: 35337972. doi:10.1016/j.annonc.2022.03.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。